| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abul Bashar Mohammad Kamrul-Hasan, Sanja Borozan, Sweekruti Jena, Lakshmi Nagendra, Deep Dutta, Saptarshi Bhattacharya, Saiful Islam and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, Academic Editor, FRCP, MD, MRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, Manchester, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Efruxifermin; Fibroblast growth factor 21; Metabolic dysfunction-associated steatohepatitis; Non-alcoholic steatohepatitis; Safety; Hepatic fat fraction |
| Core Tip |
This one is the first systematic reviews and meta-analyses specifically targeting efruxifermin (EFX)’s safety as well as liver histological and metabolic impacts in metabolic dysfunction-associated steatohepatitis (MASH). We analyzed four randomized-controlled trials (five reports) involving 450 subjects and found that EFX, imparts greater risks for drug-related treatment-emergent adverse events (TEAEs) and gastrointestinal AEs but does not increase the occurrence of severe TEAEs or serious AEs. EFX surpassed the placebo in lowering liver enzymes, urate levels, hepatic fat fraction, liver fibrosis score, Pro-C3, and liver stiffness, while also improving the fibrosis stage. Furthermore, EFX demonstrated metabolic benefits, including reductions in HbA1c and insulin resistance, along with improvements in adiponectin and lipid parameters. The outcomes of the current phase 3 trials are eagerly anticipated to verify its safety and effectiveness in MASH. |
| Publish Date |
2025-09-04 07:48 |
| Citation |
<p>Kamrul-Hasan ABM, Borozan S, Jena S, Nagendra L, Dutta D, Bhattacharya S, Islam S, Pappachan JM. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. <i>World J Gastrointest Pharmacol Ther</i> 2025; 16(3): 110709</p> |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i3/110709.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i3.110709 |
